A study investigating the persistence of respiratory effects of high-flow nasal cannula (HFNC) in stable post-extubation patients

Evaluation of the sustained physiological effects of high-flow nasal cannula in stable post-extubation patients: A randomized crossover trial comparing with conventional oxygen therapy via nasal cannula - Evaluation of the sustained physiological effects of high-flow nasal cannula in stable post-extubation patients: A randomized crossover trial comparing with conventional oxygen therapy via nasal cannula

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000061356

Enrollment

Registered

2026-05-01

Start date

2026-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute hypoxemic respiratory failure

Interventions

High-flow nasal cannula (HFNC) at 30 L/min for 30 minutes, followed by standard oxygen therapy via nasal cannula for 30 minutes. FiO2/flow adjusted to maintain SpO2 92-96%. Standard oxygen therapy via

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with acute hypoxemic respiratory failure (P/F ratio <=300) during endotracheal intubation management in ICU 2. Patients who underwent PEEP adjustment with EIT during intubation management 3. Patients who had esophageal pressure tube inserted for transpulmonary pressure monitoring during intubation management 4. Patients who used HFNC after extubation 5. Patients who have been weaned from HFNC 30%/30L for 6-24 hours or more and have oxygen requirements 6. Patients who provided written informed consent for this study

Exclusion criteria

Exclusion criteria: 1. Pregnant or breastfeeding 2. Age under 18 years 3. Consciousness disturbance 4. Pneumothorax findings on chest X-ray or CT 5. COPD GOLD stage IV 6. Contraindication to esophageal pressure measurement and/or EIT (electrical impedance tomography) monitoring 7. Patients with tracheostomy 8. End-of-life status or palliative care goals 9. Other patients judged inappropriate by the investigator

Design outcomes

Primary

Measure	Time frame
Global EELZ (End-Expiratory Lung Impedance): End-expiratory lung impedance measured by EIT, reflecting functional residual capacity and serving as a surrogate marker of PEEP effect by HFNC.	—

Secondary

Measure	Time frame
EIT measurements: Ventral EELZ, Dorsal EELZ, GI index, Ventral/Dorsal ventilation ratio, Global deltaZ, Ventral deltaZ, Dorsal deltaZ, Minute deltaZ Esophageal pressure balloon measurements: Delta PES, PTP Vital signs: Blood pressure, Respiratory rate, SpO2, Pulse rate, ROX index (SpO2/FiO2/RR) Blood gas analysis: PaO2, PaCO2, pH, HCO3 Patient-reported outcomes: Comfort (NRS 0-10), Dyspnea (NRS 0-10)	—

Measure

Time frame

EIT measurements: Ventral EELZ, Dorsal EELZ, GI index, Ventral/Dorsal ventilation ratio, Global deltaZ, Ventral deltaZ, Dorsal deltaZ, Minute deltaZ Esophageal pressure balloon measurements: Delta PES, PTP Vital signs: Blood pressure, Respiratory rate, SpO2, Pulse rate, ROX index (SpO2/FiO2/RR) Blood gas analysis: PaO2, PaCO2, pH, HCO3 Patient-reported outcomes: Comfort (NRS 0-10), Dyspnea (NRS 0-10)

—

Countries

Japan

Contacts

Public ContactAtsuhito Inoue

St. Marianna University School of Medicine Department of Emergency and Critical Care Medicine

atsuhito.inoue.2@marianna-u.ac.jp+81-44-977-8111(ext3931)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026